

# Jin Han

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2424089/publications.pdf>

Version: 2024-02-01

54  
papers

2,463  
citations

411340

20  
h-index

223390

49  
g-index

55  
all docs

55  
docs citations

55  
times ranked

4480  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical trajectories, healthcare resource use, and costs of long-term hematopoietic stem cell transplantation survivors: a latent class analysis. <i>Journal of Cancer Survivorship</i> , 2020, 14, 294-304.	1.5	9
2	Multisite-Occupancy-Driven Efficient Multiple Energy Transfer: A Straightforward Strategy to Achieve Single-Composition White-Light Emission in Ce <sup>3+</sup> , Tb <sup>3+</sup> , and Mn <sup>2+</sup> -Doped Silicate Phosphors. <i>Inorganic Chemistry</i> , 2020, 59, 9838-9846.	1.9	21
3	Multispectral tunability in single Eu <sup>2+</sup> -doped (Ba,Sr) <sub>5</sub> (PO <sub>4</sub> ) <sub>3</sub> Br phosphor. <i>Inorganic Chemistry Frontiers</i> , 2020, 7, 2515-2522.	3.0	10
4	Kidney ultrasound findings according to kidney function in sickle cell anemia. <i>American Journal of Hematology</i> , 2019, 94, E288-E291.	2.0	4
5	Type 2 diabetes in adults with sickle cell disease: can we dive deeper? Response to Skinner <i>et al</i> . <i>British Journal of Haematology</i> , 2019, 186, 782-783.	1.2	0
6	Maximum tolerated dose vs fixed low-dose hydroxyurea for treatment of adults with sickle cell anemia. <i>American Journal of Hematology</i> , 2019, 94, E112-E115.	2.0	7
7	Discontinuation and Nonadherence to Medications for Chronic Conditions after Hematopoietic Cell Transplantation: A 6-Year Propensity Score-Matched Cohort Study. <i>Pharmacotherapy</i> , 2019, 39, 55-66.	1.2	8
8	Laparoscopic Sleeve Gastrectomy in Sickle Cell Disease: a Case Series. <i>Obesity Surgery</i> , 2019, 29, 3762-3764.	1.1	0
9	Similar burden of type 2 diabetes among adult patients with sickle cell disease relative to African Americans in the U.S. population: a six-year population-based cohort analysis. <i>British Journal of Haematology</i> , 2019, 185, 116-127.	1.2	14
10	The morbidity and mortality of end stage renal disease in sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, E138-E141.	2.0	11
11	Use of metformin in patients with sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, E13-E15.	2.0	5
12	High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, E5-E7.	2.0	1
13	Redefinition of Crystal Structure and Bi <sup>3+</sup> Yellow Luminescence with Strong Near-Ultraviolet Excitation in La <sub>3</sub> BWO <sub>9</sub> :Bi <sup>3+</sup> Phosphor for White Light-Emitting Diodes. <i>ACS Applied Materials &amp; Interfaces</i> , 2018, 10, 13660-13668.	4.0	144
14	Program expansion of a day hospital dedicated to manage sickle cell pain. <i>American Journal of Hematology</i> , 2018, 93, E20-E21.	2.0	7
15	Erythropoiesis-stimulating agents in sickle cell anaemia. <i>British Journal of Haematology</i> , 2018, 182, 602-605.	1.2	9
16	Characterization of opioid use in sickle cell disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 479-486.	0.9	37
17	HMOX1 and acute kidney injury in sickle cell anemia. <i>Blood</i> , 2018, 132, 1621-1625.	0.6	20
18	Risk factors for vitamin D deficiency in sickle cell disease. <i>British Journal of Haematology</i> , 2018, 181, 828-835.	1.2	16

#	ARTICLE	IF	CITATIONS
19	Hydroxycarbamide adherence and cumulative dose associated with hospital readmission in sickle cell disease: a 6-year population-based cohort study. <i>British Journal of Haematology</i> , 2018, 182, 259-270.	1.2	16
20	Hemolysis and hemolysis-related complications in females vs. males with sickle cell disease. <i>American Journal of Hematology</i> , 2018, 93, E376-E380.	2.0	14
21	Reply to <sc>Ruan X</sc> et al: "A comment on pattern of opioid use in sickle cell disease". <i>American Journal of Hematology</i> , 2017, 92, E43.	2.0	1
22	Emission color tuning through manipulating the energy transfer from $\text{VO}_4^{3-}$ to $\text{Eu}^{3+}$ in single-phased $\text{LuVO}_4:\text{Eu}^{3+}$ phosphors. <i>Journal of Materials Chemistry C</i> , 2017, 5, 390-398.	2.7	83
23	APOL1, $\alpha$ -thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. <i>Haematologica</i> , 2017, 102, e1-e6.	1.7	47
24	Changing $\text{Ce}^{3+}$ Content and Codoping $\text{Mn}^{2+}$ Induced Tunable Emission and Energy Transfer in $\text{Ca}_{2.5}\text{Sr}_{0.5}\text{Al}_2\text{O}_6:\text{Ce}^{3+},\text{Mn}^{2+}$ . <i>Inorganic Chemistry</i> , 2017, 56, 241-251.	1.9	81
25	Toward $\text{Bi}^{3+}$ Red Luminescence with No Visible Reabsorption through Manageable Energy Interaction and Crystal Defect Modulation in Single $\text{Bi}^{3+}$ -Doped $\text{ZnWO}_4$ Crystal. <i>Chemistry of Materials</i> , 2017, 29, 8412-8424.	3.2	148
26	Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways. <i>Haematologica</i> , 2017, 102, e282-e284.	1.7	4
27	Outcomes of Rivaroxaban Use in Patients With Sickle Cell Disease. <i>Annals of Pharmacotherapy</i> , 2017, 51, 357-358.	0.9	15
28	Prediction on $\text{Mn}^{4+}$ -Doped Germanate Red Phosphor by Crystal Field Calculation on Basis of Exchange Charge Model: A Case Study on $\text{K}_2\text{Ge}_4\text{O}_9:\text{Mn}^{4+}$ . <i>Journal of the American Ceramic Society</i> , 2016, 99, 2388-2394.	1.9	16
29	Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb S $\alpha$ -thalassemia sickle cell disease. <i>American Journal of Hematology</i> , 2016, 91, E316-7.	2.0	1
30	Patterns of opioid use in sickle cell disease. <i>American Journal of Hematology</i> , 2016, 91, 1102-1106.	2.0	24
31	Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. <i>Pharmacotherapy</i> , 2016, 36, 1166-1172.	1.2	10
32	Safety of chronic transdermal fentanyl use in patients receiving hemodialysis. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 947-948.	0.5	8
33	Control of photoluminescence in $\text{Ca}_{3-x}\text{Y}_2\text{PO}_7$ phosphors by migration of the dopant. <i>Physica Status Solidi - Rapid Research Letters</i> , 2015, 9, 485-488.	1.2	3
34	Platelets decline during vaso-occlusive crisis as a predictor of acute chest syndrome in sickle cell disease. <i>American Journal of Hematology</i> , 2015, 90, E228-9.	2.0	12
35	Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease. <i>Pharmacotherapy</i> , 2015, 35, 696-700.	1.2	7
36	Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease. <i>Human Genetics</i> , 2015, 134, 895-904.	1.8	20

#	ARTICLE	IF	CITATIONS
37	Redistribution of Activator Tuning of Photoluminescence by Isovalent and Aliovalent Cation Substitutions in Whitlockite Phosphors. <i>Journal of Physical Chemistry C</i> , 2015, 119, 16853-16859.	1.5	45
38	Dual energy transfer controlled photoluminescence evolution in Eu and Mn co-activated $\text{Eu}^{2+}\text{Ca}_{2.7}\text{Sr}_{0.3}(\text{PO}_4)_2$ phosphors for solid-state lighting. <i>RSC Advances</i> , 2015, 5, 98026-98032.	1.7	7
39	Preparation and Luminescence Properties of $\text{Eu}^{2+}$ and $\text{Mn}^{2+}$ Coactivated Tricalcium Phosphate Phosphors. <i>Journal of the American Ceramic Society</i> , 2014, 97, 3631-3635.	1.9	12
40	Multicolor Emission in a Single-Phase Phosphor $\text{Ca}_3\text{Al}_2\text{O}_6:\text{Ce}^{3+},\text{Li}^+$ : Luminescence and Site Occupancy. <i>Journal of the American Ceramic Society</i> , 2014, 97, 1517-1522.	1.9	37
41	Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1469-1475.	1.4	10
42	Association of Aldosterone Synthase Polymorphism (CYP11B2 -344T>C) and Genetic Ancestry with Atrial Fibrillation and Serum Aldosterone in African Americans with Heart Failure. <i>PLoS ONE</i> , 2013, 8, e71268.	1.1	14
43	Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells following DNA Damage. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2311-2320.	1.9	16
44	The redox-sensitive cation channel TRPM2 modulates phagocyte ROS production and inflammation. <i>Nature Immunology</i> , 2012, 13, 29-34.	7.0	195
45	Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15. <i>Journal of Experimental Medicine</i> , 2009, 206, 707-719.	4.2	81
46	Intrathymic proliferation wave essential for $\text{V}\alpha 14$ natural killer T cell development depends on c-Myc. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8641-8646.	3.3	100
47	The Transcription Factor PLZF Directs the Effector Program of the NKT Cell Lineage. <i>Immunity</i> , 2008, 29, 391-403.	6.6	637
48	Actin-Binding Protein 1 Regulates B Cell Receptor-Mediated Antigen Processing and Presentation in Response to B Cell Receptor Activation. <i>Journal of Immunology</i> , 2008, 180, 6685-6695.	0.4	51
49	Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses. <i>Nature Immunology</i> , 2007, 8, 84-91.	7.0	156
50	HIP-55 Is Important for T-Cell Proliferation, Cytokine Production, and Immune Responses. <i>Molecular and Cellular Biology</i> , 2005, 25, 6869-6878.	1.1	56
51	Identification of CELF splicing activation and repression domains in vivo. <i>Nucleic Acids Research</i> , 2005, 33, 2769-2780.	6.5	41
52	ETR-3 and CELF4 protein domains required for RNA binding and splicing activity in vivo. <i>Nucleic Acids Research</i> , 2004, 32, 1232-1241.	6.5	38
53	The SH3 Domain-containing Adaptor HIP-55 Mediates c-Jun N-terminal Kinase Activation in T Cell Receptor Signaling. <i>Journal of Biological Chemistry</i> , 2003, 278, 52195-52202.	1.6	51
54	Phenylethyl Isothiocyanate Induces Apoptotic Signaling via Suppressing Phosphatase Activity against c-Jun N-terminal Kinase. <i>Journal of Biological Chemistry</i> , 2002, 277, 39334-39342.	1.6	81